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IMPORTANCE Approximately one-third of patients considered for coronary revascularization
have diabetes, which is a major determinant of clinical outcomes, often influencing the choice
of the revascularization strategy. The usefulness of fractional flow reserve (FFR) to guide
treatment in this population is understudied and has been questioned.
OBJECTIVE To evaluate the usefulness and rate of major adverse cardiovascular events
(MACE) of integrating FFR in management decisions for patients with diabetes who undergo
coronary angiography.
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used data from the
PRIME-FFR study derived from the merger of the POST-IT study (Portuguese Study on the
Evaluation of FFR-Guided Treatment of Coronary Disease [March 2012-November 2013])
and R3F study (French Study of FFR Integrated Multicenter Registries Implementation of
FFR in Routine Practice [October 2008-June 2010]), 2 prospective multicenter registries
that shared a common design. A population of all-comers for whom angiography disclosed
ambiguous lesions was analyzed for rates, patterns, and outcomes associated with
management reclassification, including revascularization deferral, in patients with vs
without diabetes. Data analysis was performed from June to August 2018.
MAIN OUTCOMES AND MEASURES Death from any cause, myocardial infarction, or unplanned
revascularization (MACE) at 1 year.
RESULTS Among 1983 patients (1503 [77%] male; mean [SD] age, 65 [10] years), 701 had
diabetes, and FFR was performed for 1.4 lesions per patient (58.2% of lesions in the left
anterior descending artery; mean [SD] stenosis, 56% [11%]; mean [SD] FFR, 0.81 [0.01]).
Reclassification by FFR was high and similar in patients with and without diabetes (41.2%
vs 37.5%, P = .13), but reclassification from medical treatment to revascularization was more
frequent in the former (142 of 342 [41.5%] vs 230 of 730 [31.5%], P = .001). There was
no statistical difference between the 1-year rates of MACE in reclassified (9.7%) and
nonreclassified patients (12.0%) (P = .37). Among patients with diabetes, FFR-based deferral
identified patients with a lower risk of MACE at 12 months (25 of 296 [8.4%]) compared with
those undergoing revascularization (47 of 257 [13.1%]) (P = .04), and the rate was of the
same magnitude of the observed rate among deferred patients without diabetes (7.9%,
P = .87). Status of insulin treatment had no association with outcomes. Patients (6.6% of
the population) in whom FFR was disregarded had the highest MACE rates regardless of
diabetes status.
CONCLUSIONS AND RELEVANCE Routine integration of FFR for the management of coronary
artery disease in patients with diabetes may be associated with a high rate of treatment
reclassification. Management strategies guided by FFR, including revascularization deferral,
may be useful for patients with diabetes.
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F ractional flow reserve (FFR)–guided revascularizationhas been shown to be superior to angiography-guidedrevascularization in reducing both short- and long-
term major adverse cardiovascular events (MACE),1,2 and
deferral of nonischemic lesions has been associated with im-
proved outcomes.3 In addition, several studies4-9 have sug-
gested that routine use of FFR is associated with a high rate
of change in treatment decisions (up to 44%) and that reclas-
sification (against angiography) is safe.
Patients with diabetes represent one-third of the popula-
tion considered for coronary revascularization. Also, diabe-
tes is often associated with a more deleterious clinical
outcome, which in turn may be affected by the choice of re-
vascularization method.10 Although there is a need for opti-
mizing clinical decisions, concerns about microcirculatory re-
sponsiveness and the potential for accelerated atherosclerosis
have cast doubts on the usefulness of FFR among patients with
diabetes.11 Data on this subject are scarce, derived from a lim-
ited number of retrospective small cohorts, and findings are
conflicting.12-16
With use of data from the large, multicenter PRIME-FFR
(POST-IT [Portuguese Study on the Evaluation of FFR-
Guided Treatment of Coronary Disease] and R3F [French Study
of FFR Integrated Multicenter Registries–Implementation of
FFR in Routine Practice]) joint international prospective
study,5,7 we aimed to describe and evaluate the routine use of
FFR among patients with diabetes for whom diagnostic coro-
nary angiography disclosed at least 1 intermediate stenosis. In
particular, we sought to describe the rate of reclassification of
the patient management strategy, evaluate such change among
patients with diabetes compared with those without diabe-
tes, describe the rate of revascularization deferral, and com-
pare the rates of MACE at 1 year in deferred patients with dia-
betes vs deferred patients without diabetes.
Methods
Patient Population
This cross-sectional study used data from the PRIME-FFR
population (n = 1983), which resulted from the merger of the
R3F (October 2008-June 2010) and POST-IT cohorts (March
2012-November 2013).5,7,8 These nationwide prospective stud-
ies shared a common design and objective dedicated to inves-
tigating the routine use of FFR at the time of diagnostic angi-
ography and its association with patient management decisions
and 1-year clinical outcomes. A total of 1983 patients were re-
ferred for coronary angiography in 40 European centers and
prospectively included in the registries. The R3F and POST-IT
studies were approved by the relevant institutional review
boards or ethics committees. The R3F study was also ap-
proved by the Commission National Informatique et Liberté.
All patients provided written informed consent to clinical fol-
low-up and to storage and use of their clinical data. All data
had been deidentified before storage.
In both studies, baseline clinical and angiographic mea-
sures were prospectively recorded in dedicated electronic
case report forms. Inclusion and exclusion criteria for each
of the original registries and definition of clinical character-
istics (including diabetes) are provided in the eMethods in
the Supplement.
Angiography and FFR Procedure
Angiography and qualitative and quantitative lesion charac-
terization were performed according to standard practice and
accepted criteria. Fractional flow reserve was performed
through diagnostic or interventional catheters and after in-
jection of intracoronary nitrate. Hyperemia was achieved using
adenosine administered through intracoronary bolus (≥100 μg)
or intravenous infusion (>140 μg/kg/min) according to local
practice. Extensive FFR evaluation was not mandated, and the
operators decided which lesions or vessels to investigate.
Analyses were performed according to the validated FFR
threshold (0.80).
Management Strategy and Definition of Reclassification
and Deferral
Investigators were required to prospectively define a base-
line management strategy for each patient based on coronary
angiography findings and all available clinical information be-
fore FFR measurement was performed. After FFR was evalu-
ated, a final management strategy was defined and recorded.
Fractional flow reserve was considered to have been disre-
garded whenever treatment was performed contrary to the FFR
result (eg, revascularization when FFR was >0.80 or the
opposite).
Options included medical therapy (with or without addi-
tional stress test), percutaneous coronary intervention (PCI),
or coronary artery bypass surgery (CABG). Patients for whom
a hybrid approach was chosen were classified in the CABG
group. When a final decision of revascularization was de-
cided, it was performed immediately or at a later stage. Re-
classification of patient management strategy was defined as
discordance between the baseline and final strategies. Revas-
cularization deferral was identified when the final strategy was
medical treatment for all lesions after FFR and no revascular-
Key Points
Question What are the usefulness, rate of major adverse
cardiovascular events (MACE), and clinical outcomes of routinely
integrating fractional flow reserve in the management strategy
for patients with diabetes who undergo coronary angiography?
Findings In this cross-sectional study of 1983 patients, overall
reclassification by fractional flow rate was high and similar in
patients with diabetes (41.2%) and patients without diabetes
(37.5%); however, reclassification from medical treatment to
revascularization was more frequent among patients with
diabetes. The rate of 1-year MACE was similar in reclassified
(9.7%) and nonreclassified (12.0%) patients with diabetes, and
the rate of MACE of patients deferred based on fractional flow
reserve was similar among those with and without diabetes.
Meaning The findings suggest that management strategies
guided by fractional flow reserve, including revascularization
deferral, may be useful for patients with diabetes.
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ization procedure was either performed or planned for that
patient.
Detailed Objectives
The objective was to describe and evaluate the usefulness and
rate of MACE of routine use of FFR among patients with dia-
betes for whom diagnostic coronary angiography disclosed at
least 1 intermediate stenosis. In particular, we aimed to de-
scribe the rate of reclassification of patient management strat-
egy and to evaluate such change in patients with diabetes com-
pared with those without diabetes. We compared the rate of
1-year MACE according to the agreement or divergence of the
FFR-guided final decision vs the a priori strategy suggested
based on angiography findings. In addition, we aimed to de-
scribe the rate of revascularization deferral and to compare rate
of 1-year MACE in deferred patients with diabetes vs deferred
patients without diabetes.
As secondary analyses, we evaluated the outcome of pa-
tients in whom the results of FFR measurement were disre-
garded by the investigators when deciding the final strategy,
as well as the potential association of insulin treatment with
FFR-based management.
Clinical Follow-up and End Points
The study primary end point (MACE) was a composite of all-
cause death, myocardial infarction, or unplanned revascular-
ization at 12 months. Each individual end point was reviewed
and adjudicated by an independent clinical event commit-
tee, and external monitoring was performed in both regis-
tries. Angina status was also obtained at 1-year follow-up. Myo-
cardial infarction was defined according to the third 2012
European Society of Cardiology/American College of Cardiol-
ogy Foundation/American Heart Association/World Heart Fed-
eration universal definition of myocardial infarction.8,17 Re-
vascularization was considered to be unplanned when it was
not performed or planned at the time of the index procedure.
Thus, both staged PCI and elective CABG resulting from the
index FFR evaluation were not considered as events.
Statistical Analysis
Before merging R3F and POST-IT into the PRIME-FFR data set,
interim comparisons were made to verify that no major hetero-
geneity existed in main baseline characteristics of study pa-
tients (including epidemiologic, clinical, and angiographic char-
acteristics and FFR) or the 1-year clinical outcome of the 2 study
cohorts overall and within subgroups (patients with diabetes
and patients without diabetes). To check for the consistency
of the results, we replicated the POST-IT analysis on the 3RF
database and vice versa.
Continuous variables are presented as means (SDs). Dis-
crete variables are presented as quantities and percentages. For
patient-related characteristics, differences among groups were
evaluated using a t test or χ2 test. The initial and final man-
agement strategy (medical therapy, PCI, and CABG) and over-
all decision to reclassify were evaluated using a Fisher exact
test. Fractional flow reserve was compared between patients
with and without diabetes according to lesion stenosis sever-
ity and lesion complexity.
Cumulative rates of MACE were estimated using the Ka-
plan-Meier method. Differences in outcomes were tested using
multivariable Cox proportional hazards models adjusted for
relevant baseline characteristics. Multiple imputation was used
to account for missing covariate data in the Cox proportional
hazards models. Analyses were conducted using SAS, ver-
sion 9.4 (SAS Institute Inc) and the level of statistical signifi-
cance was set at 2-sided P < .05. Data analysis was performed
from June to August 2018.
Results
Baseline Clinical Characteristics
The main clinical characteristics of patients are summarized
in Table 1. Of the 1983 patients (1503 [77%] male; mean [SD]
age, 65 [10] years) included in this study, 701 (35.3%) were iden-
tified as having diabetes based on study criteria, including 175
(8.8%) requiring insulin treatment. Patients with diabetes had
a typical clinical profile of such a population; compared with
patients without diabetes, they were older (mean [SD] age, 65.5
[9.6] years vs 64.6 [10.9] years, P = .05) and more likely to be
women (206 of 701 [29.4%] vs 274 of 1282 [21.4%], P < .001),
to be hypertensive (590 of 701 [84.2%] vs 848 of 1282 [68.7%],
P < .001), and to have hypercholesterolemia (544 [77.7%] vs
835 [67.9%], P < .001) but were less likely to be smokers (228
[32.5%] vs 564 [44.0%], P < .001). Patients with diabetes were
also more likely to have a left ventricular ejection fraction less
than or equal to 50% (151 [21.5%] vs 182 [14.2%], P < .001) and
to receive secondary prevention medications (any antiplate-
let: 601 [87.1%] vs 1048 [82.5%], P = .01; statin: 563 [81.7%] vs
954 [75.3%], P = .001; angiotensin-converting enzyme inhibi-
tor/angiotensin receptor blocker: 470 [68.6%] vs 688 [55.0%],
P < .001; β-blockers: 445 [65.0%] vs 753 [59.8%], P = .03)
(Table 1).
FFR and Angiographic Characteristics
The main FFR and angiographic characteristics are reported
in eTable 1 in the Supplement. Patients with diabetes vs those
without diabetes were more likely to have multivessel coro-
nary artery disease (CAD) (347 of 701 [49.5%] vs 506 of 1282
[39.4%], P < .001) and to have FFR evaluation more exten-
sively performed (1.4 vs 1.3 lesions/patient, P = .007). Among
patients with diabetes, the investigated lesion was located in
the left anterior descending artery in 582 of 1000 cases (58.2%)
and was proximal in 333 of 1000 cases (33.3%). Lesions were
in the 30% to 70% stenosis range in 782 of 1000 (78.2%) of
cases. Despite mean (SD) percentage of angiographic stenosis
being similar, patients with diabetes had more complex B2/C
lesions (422 of 1000 [42.2%] vs 645 of 1698 [38.1%], P = .03)
and FFR was lower (mean [SD]: 0.81 [0.10] vs 0.82 [0.10],
P < .001). Ischemic lesions (FFR ≤0.80) were more frequent
in patients with diabetes (458 of 1000 [45.8%] vs 616 of
1698 [36.3%], P < .001). In both groups, FFR had a normal
distribution (eFigure 1 in the Supplement), and within each
stratum of stenosis severity, FFR was significantly lower in pa-
tients with diabetes (eFigure 2 in the Supplement). Multivari-
able analyses of clinical, angiographic, and procedural
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characteristics identified the same variables associated with
a lower FFR value in both groups: age, left anterior descend-
ing artery location, American College of Cardiology/
American Heart Association lesion type, stenosis percent-
age, lesion length, and number of diseased vessels. Specific
differences in FFR assessment methods, including route of
adenosine injection and catheter size, were not associated
with FFR.
Diabetes and Clinical Outcome
Regardless of FFR and FFR-based decision, patients with dia-
betes had a higher rate of MACE (79 of 701 [11.3%] vs 116 of 1282
[9.0%]) and of death or myocardial infarction (37 of 701 [5.3%]
vs 46 of 1282 [3.6%]) (eTable 2 in the Supplement). The pro-
portion of patients free from angina at 1 year was similar
(643 of 701 [91.7%] vs 1179 of 1282 [92.0%], P = .92).
FFR-Based Reclassification of Treatment Strategy
In most procedures, physicians used the information pro-
vided by FFR to drive their final management decision in pa-
tients with diabetes (653 of 701 [93.2%]) and patients with-
out diabetes (1199 of 1282 [93.5%]) (Figure 1). The overall rate
of FFR-based treatment change was numerically higher in pa-
tients with diabetes (269 of 653 [41.2%] vs 450 of 1199 [37.5%],
P = .13). However, as shown in Figure 2, the reclassification pat-
tern diverged significantly. Specifically, patients with diabe-
tes initially considered for medical treatment were more likely
to be reclassified to a revascularization strategy (142 of 342
[41.5%] vs 230 of 730 [31.5%], P = .001) (eFigure 3 in the Supple-
ment). Patients with diabetes considered a priori for CABG were
less likely reclassified to PCI or medical treatment (22 of 59
[37.3%] vs 29 of 51 [56.8%], P = .03) (Figure 2). The propor-
tion of patients finally undergoing revascularization (PCI or
CABG) after FFR was higher among those with diabetes (344
of 653 [52.7%] vs 522 of 1199 [43.5%], P = .001). Baseline clini-
cal and angiographic characteristics of patients for whom the
use of FFR was associated with reclassification of manage-
ment strategy are presented in Table 1 and eTable 1 in the
Supplement. In both patient groups, those reclassified were
more likely to have multivessel CAD, a left anterior descend-
ing artery lesion interrogated, and lower and more frequent
ischemic FFR.
Clinical Outcome in Patients With Diabetes
and FFR Reclassification
Among the patients with diabetes in whom FFR was used for
decision reclassification of the management strategy (ie, FFR-
based decision discordant with angiography findings), the
1-year clinical outcome was as good for those for whom the de-
cision was not reclassified by FFR (ie, FFR-based decision con-
cordant with angiography findings). One-year MACE rates were
9.7% vs 12.0% (log-rank P = .37), respectively (Figure 1 and
Figure 3A and eTable 3 in the Supplement). Similarly, no
increase in clinical events was observed in reclassified vs non-
reclassified patients with diabetes, including death or myo-
cardial infarction (10 of 269 [3.7%] vs 22 of 384 [5.7%], log-
rank P = .25), myocardial infarction alone (3 of 269 [1.1%] vs
10 of 384 [2.6%], log-rank P = .18), or unplanned revascular-Ta
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ization (16 of 269 [5.9%] vs 31 of 384 [8.1%], log-rank P = .30).
These findings were not modified after multivariable adjust-
ment (eTables 3 and 4 in the Supplement). As previously re-
ported, reclassification of the management strategy was also
associated with a low rate of MACE for patients without dia-
betes (Figure 1 and Figure 3A) (eTable 3 in the Supplement).
FFR-Based Deferral of Revascularization
in Patients With Diabetes
Deferral of all lesions was less frequent in patients with dia-
betes (296 of 653 [45.3%]) compared with those without dia-
betes (662 of 1199 [55.2%]) (P < .001) (Table 2). The main clini-
cal, angiographic, and FFR characteristics of deferred patients
are reported in eTable 5 in the Supplement. Deferred patients
had significantly less extensive and less complex CAD, and FFR
was higher than in those deemed to need revascularization.
Among patients with diabetes, FFR-based deferral identified
a group of patients with a lower risk of MACE at 12 months (25
of 296 [8.4%]) compared with those undergoing revascular-
ization (47 of 257 [13.1%]) (P = .04), and the rate was of the same
magnitude of the observed rate among deferred patients with-
out diabetes (52 of 662 [7.9%], P = .87) (Table 2 and Figure 3B).
The occurrence of the individual clinical end points was con-
sistently lower in deferred vs nondeferred patients with dia-
betes (Table 2) (eTable 4 in the Supplement).
Interaction of Insulin Treatment With Reclassification
and Outcome
Compared with patients with noninsulin-dependent diabe-
tes, those with insulin-dependent diabetes had more angio-
graphically defined multivessel CAD (103 of 175 [68.8%] vs
244 of 526 [46.5%], P = .01) (eTable 6 in the Supplement)
and higher 1-year rates of MACE (24 of 175 [13.8%] vs 55 of
526 [10.4%], P = .21) and death or myocardial infarction (12
of 175 [6.9%] vs 25 of 526 [4.7%], P = .18). Although overall
reclassification rate was similar between patients with
insulin-dependent vs noninsulin-dependent diabetes (69 of
163 [42.3%] vs 200 of 490 [40.8%] patients, P = .73), less
deferral was observed (68 of 163 [41.7%] vs 228 of 490
[46.5%] patients, P = .22), and the proportion of patients
referred for CABG surgical procedure was higher in the
insulin-dependent diabetes group (29 of 163 [17.8%] vs 53 of
490 [10.8%], P = .02). Furthermore, in patients with insulin-
dependent diabetes, 1-year MACE rate was not associated
with treatment reclassification (reclassified vs nonreclassi-
fied: 10 of 69 [14.4%] vs 13 of 94 [14.0%], P = .92), and defer-
ral of revascularization was not associated with an increased
risk of 1-year MACE (deferred vs nondeferred: 7 of 68 [10.3%]
vs 16 of 95 [16.8%], P = .20) (eFigure 4 in the Supplement).
FFR-Disregarded Group: Profile
and Clinical Outcome
The baseline clinical and angiographic characteristics of the
131 patients (6.6% of the total population; 48 with diabetes
and 83 without diabetes) for whom FFR was disregarded for
the final decision are presented in Table 1 and eTable 1 in the
Supplement. Although clinical characteristics were similar be-
tween the FFR-disregarded vs FFR groups, patients for whom
FFR was disregarded had more extensive disease, longer le-
sions, and lower FFR both among patients with diabetes (0.77
vs 0.81) and patients without diabetes (0.79 vs 0.82). In most
cases (80% among patients with diabetes), lesions with an FFR
<0.80 were left untreated rather than treated (eTable 1 in the
Supplement). In this subgroup, the rate of MACE at 1 year was
Figure 1. Flowchart
1983 Patients
701 With diabetes 1282 Without diabetes
48 FFR disregarded 83 FFR disregarded
653 FFR used for decision 1199 FFR used for decision
269 Reclassified 
after FFR
384 Concordant with 
angiography
450 Reclassified 
after FFR
749 Concordant with
angiography
FFR indicates fractional flow reserve.
Figure 2. Rate of Fractional Flow Reserve–Based Reclassification
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twice as high compared with patients for whom the FFR was
included in the management strategy (17.5% vs 9.2%, P = .002)
(eTables 2 and 4 in the Supplement) (Figure 1). Similarly, pa-
tients for whom FFR was disregarded had more angina at 1 year.
Discussion
To our knowledge, this was the largest prospective study to
report the use of FFR among patients with diabetes who un-
dergo angiography and the association of FFR with treatment
decisions and clinical outcomes. The key findings can be sum-
marized as follows: (1) diabetes was not associated with higher
FFR values for any given stenosis severity; (2) treatment re-
classification was high among patients with diabetes (41.2%)
and comparable with that observed among patients without
diabetes, although the pattern of reclassification was differ-
ent; (3) integrating FFR information into patient manage-
ment was associated with a low rate of MACE among patients
with diabetes, and FFR-based deferral to medical treatment
was associated with a low rate of MACE among patients with-
out diabetes; and (4) disregarding the information derived from
FFR was associated with a worse outcome regardless of dia-
betes status.
Figure 3. Fractional Flow Reserve (FFR)–Based Decision and Clinical Outcome in the Overall Population
of Patients With Diabetes Compared With Patients Without Diabetes
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Reliability of FFR Measurements Among Patients
With Diabetes
Diabetes has the potential to impair microvascular respon-
siveness to hyperemia. As such, FFR could theoretically un-
derestimate lesion severity. However, in our study within each
stratum of stenosis severity, FFR was lower in patients with
diabetes. The evidence was not associated with higher lesion
complexity, which in turn was associated with a lower FFR.
This observation was consistent with most previous reports
(eTable 7 in the Supplement).12,16,18-21 Altogether, the find-
ings suggest that microvascular disease, when present, may
have a limited association with FFR reliability and its perfor-
mance as a risk stratification tool in this population.
Management Strategy for Patients With Diabetes and CAD
We showed that patients with and without diabetes had an
overall high and similar reclassification rate. However, the pat-
tern of change was different. Patients with diabetes were more
likely to be reclassified into a revascularization strategy (PCI
or CABG) and less likely from revascularization to medical
therapy. This finding may be the consequence of the more com-
plex disease profile, which as previously reported, was asso-
ciated with lower FFR regardless of diameter stenosis severity,5
and was further supported by the observation that within each
category of stenosis severity, FFR was lower in patients with
more complex lesions (B2/C vs A/B1).
The present study also extended to a population with dia-
betes the previous observation from both the R3F5 and the
POST-IT7 studies that the routine integration of FFR in man-
agement decisions was not associated with a reduced overall
percentage of patients undergoing revascularization (eTable 7
in the Supplement), contrary to common belief.
Rate of MACE Associated With FFR
in Patients With Diabetes
Our study showed that pursuing a treatment strategy based on
FFR that was different from that suggested by angiography
findings was not associated with worse clinical outcomes de-
spite patients with diabetes having a higher CAD burden and
complexity. Of importance, not integrating FFR in the man-
agement strategy was associated with increases in the rates of
both MACE and death or myocardial infarction in patients with
or without diabetes. Although bias (associated with unmea-
sured comorbidity, such as patient frailty and lesion complex-
ity) cannot be excluded and causality could not be deter-
mined, the findings support the importance of fully integrating
FFR findings into treatment decisions. This is in line with the
previous observations from Fractional Flow Reserve Versus
Angiography for Multivessel Evaluation 2 (FAME 2), R3F,
and POST-IT.2,5,7,22
Deferring Lesions Based on FFR and Clinical Outcome
To our knowledge, no dedicated randomized clinical trial or sub-
group analysis has specifically addressed the outcomes of le-
sions adequately deferred in the context of diabetes. A single-
center retrospective study including 250 patients recruited
during a 4-year period and representing less than 7% of the popu-
lation treated during the same period (n = 3379) observed a 10%
increase in the risk of target vessel failure among 122 deferred
patients with diabetes and FFR more than 0.80 compared with
128 deferred patients without diabetes.13,14 In the present study,
the incidence of the composite primary end point at 12 months
was similar among patients in whom all lesions were deferred
based on an FFR more than 0.80, and no revascularization was
undertaken regardless of diabetes status (Figure 3B and Table 2
and eFigure 4 and eTable 5 in the Supplement).
Overall, our results support the potential role of FFR in this
context and showed that among patients diagnosed with dia-
betes for whom clinicians felt that FFR was appropriate for de-
cision-making, an FFR value more than 0.80 may identify a
group of patients in which revascularization may be deferred
without an increase in the rate of MACE compared with pa-
tients without diabetes.
Patients Requiring Insulin
Insulin treatment has been consistently associated with the
highest risk of cardiovascular events among patients with
diabetes.10 Although hampered by the small number of pa-
tients (rendering statistical comparisons underpowered), the
pattern of clinical outcomes was consistent with the overall
population in that despite their intrinsic higher risk, insulin-
treated patients for whom revascularization was deferred based
on FFR had a numerically lower rate of MACE compared with
those warranting PCI or CABG (eFigure 4 in the Supplement).
Table 2. Clinical Outcomes at 12 Months by Management Strategy in Deferred vs Nondeferred Patients
Analysis Group
Fractional Flow Reserve Used, No. (%)
Patients With Diabetes (n = 653) Patients Without Diabetes (n = 1199)
Deferred
(n = 296)a
Nondeferred
(n = 357)b
P Value,
Log Rank
Deferred
(n = 662)a
Nondeferred
(n = 537)b
P Value,
Log Rank
P Value,
Log Rankc
Major adverse
cardiovascular event
25 (8.4) 47 (13.1) .04 52 (7.9) 48 (9.0) .50 .87
Death or myocardial
infarction
11 (3.7) 21 (5.9) .18 24 (3.6) 18 (3.4) .78 .94
Total deaths 9 (3.0) 12 (3.4) .81 17 (2.6) 12 (2.2) .70 .67
Myocardial infarction 2 (0.7) 11 (3.1) .02 8 (1.2) 8 (1.5) .67 .44
Unplanned coronary
revascularization
15 (5.1) 33 (9.2) .03 34 (5.2) 34 (6.4) .33 .96
a Deferred patients: all lesions deferred by fractional flow reserve.
b Nondeferred patients: at least 1 lesion revascularized by percutaneous
coronary intervention or coronary artery bypass graft surgery.
c Deferred diabetes vs deferred no diabetes.
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Also, there was no association of use of FFR (vs angiography
findings) and changes in management strategy according to the
FFR values vs angiography were not associated with worse
clinical outcomes.
Limitations
This study has limitations. The present study was the combi-
nation of 2 nationwide prospective FFR studies, and we can-
not exclude that unaccounted differences between the 2 co-
horts might have influenced our findings. However, the
previous published results of R3F5 and POST-IT7 as well as
the outcome analyses performed separately in each data set
showed consistency between the 2 studies.
The present study included mostly patients with interme-
diate lesions for whom the likelihood of reclassification by FFR
was expected to be high. Therefore, our results may not ex-
tend to patients with angiographically severe multivessel dis-
ease and tight lesions. In addition, our data cannot speak to
the relative safety of a strict FFR vs angiography-based ap-
proach because there was no formal control group in which pa-
tients were managed according to angiography findings alone.
However, in the FFR-disregarded group, information from an-
giography (and maybe clinical characteristics) prevailed com-
pared with information derived from the FFR, and these pa-
tients had a higher rate of MACE.
Conclusions
Among patients with diabetes and mostly intermediate coro-
nary lesions, routine use of FFR was associated with reclassi-
fication of clinical management in a significant proportion of
cases. A treatment plan guided by FFR that is divergent from
that suggested by angiography findings (including revascu-
larization deferral) was associated with good clinical out-
come in these patients. Dedicated randomized clinical trials
powered for clinical outcomes are needed to further refine the
role of FFR-based strategies (as well of other physiologic in-
dexes) for the clinical management of this important sub-
group of patients.23,24
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